Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $361,996.80 in Stock

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $51.42, for a total value of $361,996.80. Following the transaction, the chief executive officer directly owned 22,600 shares in the company, valued at $1,162,092. This trade represents a 23.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Wednesday, February 18th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.40, for a total value of $361,856.00.
• On Friday, February 13th, Jack Bendheim sold 7,040 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.96, for a total transaction of $365,798.40.
• On Wednesday, February 11th, Jack Bendheim sold 14,184 shares of Phibro Animal Health stock. The shares were sold at an average price of $51.62, for a total transaction of $732,178.08.
• On Tuesday, February 10th, Jack Bendheim sold 58,014 shares of Phibro Animal Health stock. The stock was sold at an average price of $51.81, for a total transaction of $3,005,705.34.
• On Thursday, February 5th, Jack Bendheim sold 110,842 shares of Phibro Animal Health stock. The shares were sold at an average price of $48.38, for a total transaction of $5,362,535.96.
• On Wednesday, February 4th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.15, for a total transaction of $144,848.00.
• On Tuesday, February 3rd, Jack Bendheim sold 9,660 shares of Phibro Animal Health stock. The stock was sold at an average price of $41.47, for a total transaction of $400,600.20.
• On Friday, January 30th, Jack Bendheim sold 6,693 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total value of $268,322.37.
• On Thursday, January 29th, Jack Bendheim sold 6,772 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.12, for a total value of $271,692.64.
• On Friday, January 23rd, Jack Bendheim sold 1,235 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.55, for a total value of $50,079.25.

Phibro Animal Health Trading Up 3.2%

NASDAQ PAHC opened at $53.10 on Thursday. The firm has a market capitalization of $2.15 billion, a PE ratio of 23.60, a P/E/G ratio of 0.79 and a beta of 0.80. The stock’s 50 day moving average is $43.13 and its 200 day moving average is $40.57. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $56.30. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14.

Phibro Animal Health (NASDAQ:PAHC) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.69 by $0.18. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The business had revenue of $373.91 million during the quarter, compared to analyst estimates of $355.64 million. Phibro Animal Health has set its FY 2026 guidance at 2.930-3.100 EPS. Research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Wednesday, March 4th will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Wednesday, March 4th. This represents a $0.48 annualized dividend and a yield of 0.9%. Phibro Animal Health’s payout ratio is presently 21.33%.

Institutional Trading of Phibro Animal Health

Institutional investors and hedge funds have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Phibro Animal Health by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,164 shares of the company’s stock valued at $260,000 after purchasing an additional 546 shares in the last quarter. Millennium Management LLC increased its holdings in Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after buying an additional 154,281 shares in the last quarter. Jane Street Group LLC raised its position in Phibro Animal Health by 65.3% in the 1st quarter. Jane Street Group LLC now owns 33,917 shares of the company’s stock worth $724,000 after buying an additional 13,404 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in Phibro Animal Health by 97.3% during the 2nd quarter. Envestnet Asset Management Inc. now owns 24,334 shares of the company’s stock valued at $621,000 after acquiring an additional 11,999 shares during the period. Finally, Corton Capital Inc. purchased a new stake in shares of Phibro Animal Health during the 2nd quarter valued at about $362,000. Institutional investors own 99.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on PAHC shares. JPMorgan Chase & Co. raised their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Morgan Stanley set a $49.00 price objective on Phibro Animal Health in a research report on Friday, February 6th. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 9th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Phibro Animal Health has an average rating of “Hold” and an average price target of $37.50.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.